Evaluation of the Efficacy of Calcium a -Ketoglutarate(AKG-Ca) in Lmproving Human Aging

Launched by SHENZHEN HYGIEIA BIOTECH CO., LTD · Aug 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a supplement called calcium alpha-ketoglutarate (CaAKG) can help slow down the aging process and improve health in middle-aged and older adults. CaAKG is a special form of a natural substance that plays a role in how our cells produce energy. The study will look at changes in biological aging, physical health, inflammation, blood sugar and cholesterol levels, and overall quality of life. Researchers hope to find out if taking CaAKG daily for 12 weeks is safe and beneficial for healthy aging.

Adults between 40 and 75 years old who are generally healthy and haven’t used other anti-aging products recently may be eligible to join. Participants will be randomly assigned to take either the CaAKG supplement or a placebo (a harmless pill with no active ingredient) every day for three months. Before and after the study, they will have health check-ups and complete some tests to measure changes. People with certain health conditions, like heart disease, diabetes, cancer, or severe lung problems, will not be able to join. The study is carefully reviewed by an ethics committee to ensure participant safety, and everyone will give informed consent before taking part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 40-75 years old, no gender restrictions.
• • 2. Has not taken any other anti-ageing research products in the past two months.
• • 3. Able to use a smartphone.
• • 4. Informed consent, voluntarily signed informed consent form, and agreed to participate in all visits and treatments in accordance with the trial protocol.
• Exclusion Criteria:
• • 1. Patients with cardiovascular disease, severe/uncontrolled hypertension, rheumatic heart disease, congenital heart disease, deep vein thrombosis, or pulmonary embolism .
• • 2. Patients with Type I/Type II diabetes (treated with oral metformin or insulin) or diabetes complications .
• • 3. Patients with cancer or who have undergone surgery, systemic drug therapy, or radiation therapy within the past 3 years.
• • 4. Chronic obstructive pulmonary disease (COPD), severe asthma (requiring daily medication).
• • 5. Multiple sclerosis, autoimmune/immunodeficiency disorders.
• • 6. Recent history of sepsis or infection (hospitalisation within the past 3 months).
• • 7. Any mental illness or neurodegenerative disease.
• • 8. Any metallic implants in the body.
• • 9. Hepatitis/cirrhosis.
• • 10. Severe kidney disease (GFR \<30 mL/min/1.73 m²).
• • 11. Suffering from other conditions deemed unsuitable for participation in this trial (as determined by the investigator).